Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review
一项范围界定综述表明，无论年龄、疾病严重程度或抑制剂状态如何，Emicizumab 对先天性血友病 A 患者均具有良好的耐受性和疗效。
期刊:Research and Practice in Thrombosis and Haemostasis
影响因子:3.4
doi:10.1016/j.rpth.2024.102415
Young, Guy; Pipe, Steven W; Kenet, Gili; Oldenburg, Johannes; Safavi, Mariam; Czirok, Tuende; Nissen, Francis; Mahlangu, Johnny
